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DALYs, 14.6%). For the age group 65 and over, after adjusting for population, the
burden increases 7 fold. The 3 conditions, overall, represent 2,03 DALYs per 1000
Colombians in that age range. CONCLUSIONS: Despite the lower incidence of
pneumococcal disease in adults, as compared with children, its burden is still
significant, comparable, for example, to that of schizophrenia or epilepsy in Co-
lombia. This study may provide a benchmark for future preventive interventions
and for efficient resource allocation.
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OBJECTIVES: To review the changes in HIV in terms of course of the disease over
the past five years and its consequences, to assess whether existing economic
models in HIVwould need to be updated to account for these changes in case these
were used for the economic evaluation of new treatments in HIV. METHODS: A
systematic literature review was carried out in PubMed, using both MeSH and key
words, focusing on the following areas: opportunistic infections (OIs), health con-
sequences, costs, quality of life, adherence and compliance and efficacy of treat-
ments. In addition, current guidelines were identified and reviewed. For treat-
ments we focussed on maraviroc, etravirine and raltegravir. RESULTS: At total of
1787 hits were obtained from the above-mentioned strategy. Finally data on 341
articles extracted. For treatments, data from six trials on efficacy and adverse event
datawere extracted and used in ameta-analysis (not reported here). In terms of OIs
it was clear that fewer patients suffer from these infections compared to the early
2000s. Data on costs indicated that new costs were available by CD4 cell count.
There are substantial new data available on quality of life in HIV, however, with
several publications providing data by CD4-cell strata. Data on health conse-
quences showed that patients increasingly live long enough to suffer from LT
health consequences such as cardiovascular disease and cancer. Guidelines indi-
cated that treatment algorithms had changed markedly in the last five years and
that comparison to OBT is no longer an acceptable comparator strategy in eco-
nomic modelling. CONCLUSIONS: The management of HIV has changed substan-
tially since 2006. Patients live longer, are healthier and suffer from “common”
health consequences such a cardiovascular disease and cancer. Any health eco-
nomic model in this disease area should take these aspects into consideration.
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OBJECTIVES: When modeling the course of disease it is crucial to make proper
assumptions concerning transition probabilities between health states. Two dif-
ferent approaches may be adopted: constant or time-dependent probabilities (i.e.
survival curves). Most of published economic analyses of hepatitis C treatment are
based on models with constant probabilities. Using survival curves is more time-
consuming and complex butmay result inmore accurate estimates. Our aimwas to
compare the impact of both methods on results of chronic hepatitis C modeling.
METHODS: A Markov model was developed to describe hepatitis C patients flow.
Time horizon of 50 years was chosen, cycle length was 1 year. Health states distin-
guished in the model were: fibrosis, compensated cirrhosis (CC), decompensated
cirrhosis (DC), hepatocellular carcinoma (HCC), liver transplant (LT) and death. The
possible transitions were: fibrosis-CC, CC-DC, CC-HCC, DC-HCC, DC-LT
and from each state to death. Transition probabilities between health states were
estimated based on clinical trials evaluating the natural course of chronic hepatitis
C progression: either by calculating constant yearly rates or by using Weibull
curves estimated from reported Kaplan-Meier curves (the same data source for
each transition). Time spent in each of health states was compared between those
two approaches. RESULTS:The average time spent by a CC patient in states CC, DC,
HCC and LT was 18.3, 1.6, 0.3 and 1.3 years for constant probabilities, and 14.2, 3.2,
1.1 and 1.6 years for survival curves. Average survival was 21.5 and 20.2 years,
respectively. CONCLUSIONS:Method of calculation of transition probabilities may
have a significant impact on results of modeling, which may further influence
incremental cost-effectiveness ratios in economic analyses. The decision on the
method should bemade on the base of nature of events that are beingmodeled – for
some it may be more accurate to apply the survival curves approach.
PIN67
EXTENDED COX MODEL ANALYSIS WITH NON-PROPORTIONAL HAZARDS
APPLIED IN REAL-WORLD OBSERVATIONAL DATA
Ji X1, Gao X1, Baddley JW2, Chambers R3, Solem CT1, Stephens JM1
1Pharmerit International, Bethesda, MD, USA, 2University of Alabama at Birmingham,
Birmingham, AL, USA, 3Pfizer, Inc., Collegeville, PA, USA
OBJECTIVES: To illustrate the application of an extended Cox regression model
with time-dependent treatment effects to real-world observational data.
METHODS: A retrospective US hospital database analysis was conducted among
adult invasive aspergillosis (IA) patients receiving their first antifungal therapy
during ICU stay. To assess the initial antifungal treatment effect on survival/LOS, a
survival analysiswas conductedwith event defined as “discharged alive”, censored
being “expired in hospital”, and time variable being treatment-initiation-to-dis-
charge (DITD). Key demographic, clinical and treatment variables were included.
Regimen A was the reference group and compared to regimen B (inactive against
IA, possibly indicating a treatment delay). Proportional hazard assumptions for the
treatment variable were assessed by the Schoenfeld residuals significance test.
When significant, treatment-by-time interaction together with its main effects
were included within an extended Cox model to account for the proportional haz-
ard violation. Multiple functional forms for time were considered in treatment-by-
time interactions. Due to the lack of direct SAS output for specific time points,
time-specific hazard ratios (HR) between treatments were manually calculated
incorporating bothmain effects and time covariates.RESULTS:A continuous linear
treatment-by-time interaction was constructed for Drug B since the null hypothe-
sis of Schoenfeld test was rejected. Consistent with an increasing time-interaction
effect (HR1.032, p0.0001), HR of drug B increased over time: Drug B patientswere
57% less likely (HR0.43, p.0001) to be discharged alive compared to Drug A at
mean switch time to other IA-active drugs (9 days), and 27% less likely (HR0.73,
p0.0297) to be discharged alive at mean DITD (25 days). Hazards would be equiv-
alent (HR1) at day 35, although by then most patients on regimen A (81%) had
switched/been discharged. CONCLUSIONS: The extended Coxmodel can be imple-
mented as an adjustment for the proportional hazard violation in observational
data analysis to obtain unbiased survival results.
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OBJECTIVES: In retrospective claims-based studies of drug exposures and resultant
safety/tolerability issues (TIs), researchersmust define an a-priori “at-riskwindow”
– the time period in which observed TIs are classified as resulting from drug expo-
sure. In HIV, interruption of combination antiretroviral therapy (cART) may cause
detrimental clinical outcomes; thus, if a TI necessitates a switch in cART, the
claims-based evidence of healthcare utilization for TIs may persist even after
switching. This study quantified the impact of at-risk window assignment on ret-
rospectively-estimated incidence and costs of TIs.METHODS: Data were Medicaid
claims from 15 states. Subjects were HIV patients 18–64 years old initiating
atazanavir, darunavir, fosamprenavir, or lopinavir-based cART regimens from Jan-
uary 1, 2003 to July 1, 2010. Outcomes: incidence and costs of new-onsetmedically-
attended (ICD-9-CM-coded or treated) TIs (gastrointestinal, lipid abnormalities, di-
abetes/hyperglycemia, rash, jaundice) during a period of up-to 6 months post-
cART-initiation or censoring at switch. RESULTS: Sample included 20,024 patients;
mean age 42 years, 34% female, 48% black. When extending the at-risk window for
7 days post-switch, differences in incidence rates of TIs per 1,000 patient-months
were: gastrointestinal (76.1 with extension vs. 73.7 without); lipid abnormalities
(23.5 vs. 22.3); diabetes/hyperglycemia (9.0 vs. 8.8); rash (98.5 vs. 96.0); jaundice (0.59
vs. 0.57). When extending the cost-accrual window to include costs of TIs that
persist after switching, differences in the estimated per-patient per-month (PPPM)
costs of TIs were: gastrointestinal ($72 with extension vs. $75 without); lipid abnor-
malities ($27 vs. $22); diabetes/hyperglycemia ($71 vs. $67); rash ($7 vs. $8); jaundice
($0.4 vs. $2). CONCLUSIONS: Extension of at-risk windows increased estimated
incidence rates of TIs, decreased estimated PPPM costs of acute TIs (i.e., gastroin-
testinal, rash, jaundice) and increased the estimated PPPM cost of chronic TIs (i.e.,
lipid abnormalities, diabetes/hyperglycemia). These novel results may inform fu-
ture retrospective studies of TIs in cART.
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OBJECTIVES: Atopic dermatitis is a chronically relapsing inflammatory skin con-
dition accompanied by pruritus which, when severe, can negatively impact a pa-
tient’s quality of life. The objective of this study was to perform ameta-analysis of
randomized controlled trials (RCTs) of topical therapies compared against their
vehicles, and systemic therapies compared against their placebos, and to record
how these therapies changed the magnitude of pruritus associated with atopic
dermatitis. METHODS: Data for this meta-analysis were extracted from Medline,
Embase, and the Cochrane Controlled Clinical Trials Register, as well as follow-up
references in retrieved articles from years 1977 to 2011. Initial search of systemic
therapies in relieving the pruritus of atopic dermatitis yielded 205 studies. Out of
the 205 studies, 52 studiesmet the inclusion criteria, with 41 and 11 studies involv-
ing topical and systemic treatment of pruritus of atopic dermatitis, respectively.
Standard inverse variance fixed-effects meta-analysis was used to calculate the
pooled estimates for RCTs falling under each type of treatment. RESULTS: The 52
studies were analyzed using STATA SE version 10. Meta-analysis results showed
that overall, compared to systemic medication of atopic dermatitis, the topical
medications significantly reduced atopic pruritus by 35.3% (RR, 0.647; 95%CI, 0.619-
0.677). Among the topical medications, compared to the use of vehicle, the use of
anti-histamines, calcineurin inhibitors and topical corticosteroids as therapeutic
agents significantly reduced the pruritus of atopic dermatitis by 27%, 36% and 34%
in patients, respectively. CONCLUSIONS: The topical treatments were more suc-
cessful at reducing atopic pruritus compared to the systemic treatments. Overall,
calcineurin inhibitors were the most effective antipruritic agents. Verifiable pruri-
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